
AI boosts nAMD therapy planning
A new level of insight for anti-VEGF therapy planning for neovascular age-related macular degeneration (nAMD) patients is expected with Heidelberg and deepeye Medical’s collaboration, Deepeye Therapy Planning Support (TPS).












